EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein
November 09 2020 - 8:00AM
Business Wire
Underscores importance of serological testing
using the S1 subunit for worldwide seroprevalence and vaccine
development
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to
innovating for a healthier world, announced today that EUROIMMUN, a
PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM
ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1
antigen. The assay is available for countries accepting the CE
mark, and the Company plans to file a request for this product with
the U.S. Food and Drug Administration for Emergency Use
Authorization (EUA).
This quantitative test kit applies a recombinant S1 subunit of
the SARS-CoV-2 spike protein, enabling detection of IgG antibodies.
These antibodies have been the focus of vaccine development
programs as well as discussions about possible immunity in
previously infected individuals. With this new ELISA assay,
EUROIMMUN is providing a product to support careful evaluation of
an important antibody subgroup enabling standard curve-based
quantification of the anti-S1 IgG antibody concentration.
“The global research and medical community is focused on having
an effective SARS-CoV-2 vaccine available as soon as possible, but
to do so, it’s clear that the quantitative measurement of
antibodies in clinical studies will play a huge part,“ said Dr.
Wolfgang Schlumberger, CEO of EUROIMMUN. “The EUROIMMUN assays,
especially the S1-based tests, are important tools for
pharmaceutical laboratories conducting clinical trials. Our assays
can help to identify individuals who have been exposed to
SARS-CoV-2 and may play a critical role in accurate evaluation of
antibody status before and after infection, in antibody therapies
or in vaccination programs.”
The QuantiVac ELISA assay adds to the Company’s broad product
portfolio of COVID-19 diagnostics and is based on the CE-marked and
FDA EUA-approved semi quantitative/qualitative Anti-SARS-CoV-2
ELISA (IgG).
EUROIMMUN has increased its ELISA production for COVID-19
diagnostics to more than three million tests per week and can
supply large numbers of dried blood spot collection sets for
upcoming seroprevalence and vaccination development studies. Large
international reference laboratories have implemented EUROIMMUN
SARS-CoV-2 assays, and the tests are being applied in an increasing
number of epidemiological studies worldwide.
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to
address their most critical challenges across science and
healthcare. With a mission focused on innovating for a healthier
world, we deliver unique solutions to serve the diagnostics, life
sciences, food and applied markets. We strategically partner with
customers to enable earlier and more accurate insights supported by
deep market knowledge and technical expertise. Our dedicated team
of about 13,000 employees worldwide is passionate about helping
customers work to create healthier families, improve the quality of
life, and sustain the wellbeing and longevity of people globally.
The Company reported revenue of approximately $2.9 billion in 2019,
serves customers in 190 countries, and is a component of the
S&P 500 index. Additional information is available through
1-877-PKI-NYSE, or at www.perkinelmer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201109005339/en/
Investor Relations: Bryan Kipp +1-781-663-5583
Bryan.Kipp@perkinelmer.com Media Relations: Chet Murray
+1-781-663-5719 Chet.Murray@perkinelmer.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Sep 2023 to Sep 2024